Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) — Market Cap & Net Worth

$39.27 Billion USD · Rank #682

Market Cap & Net Worth: Alnylam Pharmaceuticals Inc (ALNY)

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has a market capitalization of $39.27 Billion ($39.27 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #682 globally and #315 in its home market, demonstrating a -5.63% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alnylam Pharmaceuticals Inc's stock price $296.11 by its total outstanding shares 132623144 (132.62 Million). Analyse ALNY cash flow conversion to see how efficiently the company converts income to cash.

Alnylam Pharmaceuticals Inc Market Cap History: 2015 to 2026

Alnylam Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $12.49 Billion to $39.27 Billion (12.64% CAGR).

Index Memberships

Alnylam Pharmaceuticals Inc is a constituent of 5 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
ARCA Biotechnology BTK	$910.33 Billion	4.31%	#6 of 30
Dow Jones Biotechnology DJUSBT	$1.09 Trillion	3.61%	#6 of 39
NASDAQ Health Care IXHC	$2.41 Trillion	1.63%	#9 of 976
NASDAQ Composite IXIC	$38.77 Trillion	0.10%	#94 of 3165
NASDAQ Biotechnology NBI	$1.67 Trillion	2.35%	#7 of 263

Weight: Alnylam Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Alnylam Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Alnylam Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

14.20x

Alnylam Pharmaceuticals Inc's market cap is 14.20 times its annual revenue

Industry average: 3784.39x Lower than industry average

Latest Price to Earnings (P/E) Ratio

168.09x

Alnylam Pharmaceuticals Inc's market cap is 168.09 times its annual earnings

Industry average: 0.19x Higher than industry average

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2016	$4.97 Billion	$47.16 Million	-$410.11 Million	105.29x	N/A
2017	$16.85 Billion	$89.91 Million	-$490.87 Million	187.40x	N/A
2018	$9.67 Billion	$74.91 Million	-$761.50 Million	129.09x	N/A
2019	$15.27 Billion	$219.75 Million	-$886.12 Million	69.51x	N/A
2020	$17.24 Billion	$492.85 Million	-$858.28 Million	34.97x	N/A
2021	$22.49 Billion	$844.29 Million	-$852.82 Million	26.64x	N/A
2022	$31.52 Billion	$1.04 Billion	-$1.13 Billion	30.38x	N/A
2023	$25.39 Billion	$1.83 Billion	-$440.24 Million	13.88x	N/A
2024	$31.21 Billion	$2.25 Billion	-$278.16 Million	13.88x	N/A
2025	$52.74 Billion	$3.71 Billion	$313.75 Million	14.20x	168.09x

Competitor Companies of ALNY by Market Capitalization

Companies near Alnylam Pharmaceuticals Inc in the global market cap rankings as of May 2, 2026.

Key companies related to Alnylam Pharmaceuticals Inc by market ranking:

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#223	Vertex Pharmaceuticals Inc	NASDAQ:VRTX	$107.56 Billion	$423.92
#367	Regeneron Pharmaceuticals Inc	NASDAQ:REGN	$72.88 Billion	$701.42
#517	UCB SA	BR:UCB	$51.45 Billion	€231.20
#568	argenx NV ADR	NASDAQ:ARGX	$45.97 Billion	$787.95

Alnylam Pharmaceuticals Inc Historical Marketcap From 2015 to 2026

Between 2015 and today, Alnylam Pharmaceuticals Inc's market cap moved from $12.49 Billion to $ 39.27 Billion, with a yearly change of 12.64%.

Year	Market Cap	Change (%)
2026	$39.27 Billion	-25.54%
2025	$52.74 Billion	+68.99%
2024	$31.21 Billion	+22.94%
2023	$25.39 Billion	-19.46%
2022	$31.52 Billion	+40.14%
2021	$22.49 Billion	+30.48%
2020	$17.24 Billion	+12.85%
2019	$15.27 Billion	+57.96%
2018	$9.67 Billion	-42.61%
2017	$16.85 Billion	+239.34%
2016	$4.97 Billion	-60.23%
2015	$12.49 Billion	--

End of Day Market Cap According to Different Sources

On May 2nd, 2026 the market cap of Alnylam Pharmaceuticals Inc was reported to be:

Source	Market Cap
Yahoo Finance	$39.27 Billion USD
MoneyControl	$39.27 Billion USD
MarketWatch	$39.27 Billion USD
marketcap.company	$39.27 Billion USD
Reuters	$39.27 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Alnylam Pharmaceuticals Inc

NASDAQ:ALNY USA Biotechnology

Market Cap

$39.27 Billion

Market Cap Rank

#682 Global

#315 in USA

Share Price

$296.11

Change (1 day)

-4.32%

52-Week Range

$251.15 - $491.22

All Time High

$491.22